Palvella Therapeutics (PVLA) EBITDA Margin (2014 - 2024)
Palvella Therapeutics' (PVLA) quarterly EBITDA Margin came in at 3318.87% in Q1 2024, down 254718.0% year-on-year from N/an in Q2 2023, and down 594.22% on a QoQ basis from 478.07% in Q4 2023.
Palvella Therapeutics (PVLA) EBITDA Margin (2014 - 2024) Analysis & Trends
Palvella Therapeutics (PVLA) has 11 years of EBITDA Margin data on file, last reported at 3318.87% in Q1 2024.
- On a quarterly basis, EBITDA Margin fell 254718.0% year-over-year to 3318.87% in Q1 2024; TTM through Sep 2024 was 133.13%, a 4499.0% decrease from a year earlier, with the FY2023 full-year figure at 30.66%, up 1000952.0% from the prior year.
- EBITDA Margin for Q1 2024 stood at 3318.87%, down from 478.07% in the prior quarter.
- Over the last five years, EBITDA Margin for PVLA reached as high as 351.09% in Q4 2020 and fell as low as 8408.03% in Q4 2022.
- Historically, EBITDA Margin has averaged 1546.13% across 5 years, with a median of 468.62% in 2021.
- Across the five-year window, EBITDA Margin slumped 827776 bps in 2022 and soared 792996 bps in 2023, its largest moves.
- Year by year, EBITDA Margin stood at 351.09% in 2020, then sank by 137 bps to 130.27% in 2021, then sank by 6354 bps to 8408.03% in 2022, then jumped by 94 bps to 478.07% in 2023, then slumped by 594 bps to 3318.87% in 2024.
- Per Business Quant data, the three most recent EBITDA Margin figures were 3318.87% in Q1 2024, 478.07% in Q4 2023, and 60.49% in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Palvella Therapeutics | 318.78 Mn | 56.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -3,318.87% |
| Dec 31, 2023 | -478.07% |
| Sep 30, 2023 | -60.49% |
| Jun 30, 2023 | 10.29% |
| Mar 31, 2023 | -771.69% |
| Dec 31, 2022 | -8,408.03% |
| Sep 30, 2022 | -4,716.28% |
| Jun 30, 2022 | -5,360.87% |
| Mar 31, 2022 | -67.86% |
| Dec 31, 2021 | -130.27% |
| Sep 30, 2021 | -468.62% |
| Jun 30, 2021 | -2,249.80% |
| Mar 31, 2021 | -38.92% |
| Dec 31, 2020 | 351.09% |
| Sep 30, 2020 | -504.23% |
| Jun 30, 2020 | -42.59% |
| Mar 31, 2020 | -29.08% |
| Dec 31, 2019 | -7.70% |
| Sep 30, 2019 | -19.26% |
| Jun 30, 2019 | -229.37% |